Evidence map›Paper›PMID 32817227›Full record

ArticleJournal of clinical microbiology2020

Testing of

Ricardo Gianecini, Lucia Irazu, Marcelo Rodríguez, Paula Cristaldo, Claudia Oviedo, Marisa Turco, Veronica Rodrigo, Liliana Fernández Canigia, Ana Schneider, Liliana Guelfand and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Ricardo GianeciniWorld Health Organization Collaborating Centre for Antimicrobial Resistance, National Reference Laboratory of Sexually Transmitted Diseases (STD), National Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Lucia IrazuNational Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Marcelo RodríguezNational Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Paula CristaldoWorld Health Organization Collaborating Centre for Antimicrobial Resistance, National Reference Laboratory of Sexually Transmitted Diseases (STD), National Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Claudia OviedoWorld Health Organization Collaborating Centre for Antimicrobial Resistance, National Reference Laboratory of Sexually Transmitted Diseases (STD), National Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Marisa TurcoSección Microbiología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Veronica RodrigoSección Microbiología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
Liliana Fernández CanigiaLaboratorio Bacteriología, Hospital Alemán, Buenos Aires, Argentina.
Ana SchneiderLaboratorio Bacteriología, Hospital Alemán, Buenos Aires, Argentina.
Liliana GuelfandLaboratorio Bacteriología, Hospital Fernández, Buenos Aires, Argentina.
Laura ScocozzaLaboratorio Bacteriología, Hospital Fernández, Buenos Aires, Argentina.
GASSP-AR Working Group
Patricia GalarzaWorld Health Organization Collaborating Centre for Antimicrobial Resistance, National Reference Laboratory of Sexually Transmitted Diseases (STD), National Institute of Infectious Diseases-ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina pgalarza@anlis.gov.ar.ORCID 0000-0001-5186-9222
Administración Nacional de Laboratorios e Institutos de Salud · ARHospital Alemán · ARHospital Fernández · ARHospital General de Niños Ricardo Gutierrez · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azithromycin in combination with ceftriaxone is recommended as the first-line treatment for uncomplicated gonorrhea in many countries. Therefore, monitoring of azithromycin susceptibility of

Indexed as

GonorrheaNeisseria gonorrhoeaeAgarAnti-Bacterial AgentsAzithromycinHumansMicrobial Sensitivity TestsAgarAnti-Bacterial AgentsAzithromycinazithromycindisk diffusionNeisseria gonorrhoeae

Identifiers

PMID32817227
PMCPMC7587106
OpenAlexW3048784711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.